5301 Stevens Creek Blvd
23 articles with Agilent Technologies
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)
PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab)
Respondents included 650 laboratory managers, directors, and supervisors from China, Germany, India, South Korea, Switzerland, Austria, and the United States.
Agilent Technologies Inc. (NYSE: A) today announced the following upcoming webcasts for the investment community:
Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development
Agilent Technologies Inc. (NYSE: A) today announced that Professor Antoni Ribas has received an Agilent Thought Leader Award in support of his genomics and immunotherapy research.
Agilent Technologies Inc. (NYSE: A) today announced that it will host the western regional conference of the National Academy of Engineering, along with a technical symposium—Bioengineering, Advancing Our World—at company headquarters in Santa Clara, California, on March 28, 2019.
Belgian scientist recognized for his research in cancer genomics
Agilent Technologies to Host Webcast of First-Quarter Fiscal Year 2019 Financial Results Conference Call
Agilent Technologies Inc. (NYSE: A) will release first-quarter fiscal 2019 financial results after the stock market closes on February 20.
Agilent Sends Letter to the SEC Regarding Material Misstatements in Twist Bioscience’s S-1 Registration Statement
Agilent Technologies Inc. (NYSE: A) today announced that it sent a letter to the Division of Corporation Finance of the U.S. Securities and Exchange Commission (SEC) regarding misstatements in the S-1 Registration Statement filed by Twist Bioscience Corp.
Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.
Cell Analysis Just Got Better!
8/13/2018GSK's Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let's take a look at some of those!
PD-L1 IHC 22C3 pharmDx Can Now Be Used as an Aid to Identify Urothelial Carcinoma Patients for Treatment With KEYTRUDA® (pembrolizumab)
Agilent Technologies Inc. today announced the release of a range of new probes for in situ hybridization.
System can now employ three analytical techniques simultaneously.
Agilent Technologies, Inc. announced that it has completed the acquisition of Advanced Analytical Technologies, Inc. (AATI).
Acquisition enhances Agilent’s current software portfolio, adding LIMS and workflow management, while expanding ELN capability.
Agilent Technologies Inc. (NYSE: A) today announced the Agilent Seahorse XF Real-Time ATP Rate Assay Kit, a new product that will enable biologists to enhance their understanding of how live-cells function in real-time.
Laboratory Designed to Meet Demand for Fully Tested Solutions in Pharma, Biopharma and Food Analysis
Agilent Technologies announced that it will showcase its line-up of innovative solutions for laboratory efficiency at Analytica, being held April 10 – 13, in Munich, Germany.